id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2525-0006,FDA,FDA-2016-E-2525,Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT INJECTION New Drug Application 205837,Notice,Determinations,2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,2020-02-11T04:59:59Z,2020-01-28T02:04:02Z,2019-26812,0,0,0900006484206a35
FDA-2016-E-2525-0005,FDA,FDA-2016-E-2525,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T17:17:45Z,,0,0,0900006484115ddb